Virginia (202) 466-6937

Author: Peter Arhangelsky

Press Release: Emord & Associates’ Legal Analysis of Vermont Genetically Engineered Labeling Bill, H.112, Concludes Bill Is Constitutional

Posted on by Peter Arhangelsky

Emord & Associates, P.C. is an AV-rated (highest in legal ability and ethics, Martindale-Hubbell organization) constitutional and administrative law firm located in Washington, D.C., Clifton, Virginia, and Chandler, Arizona (see emord.com).  The firm has represented clients in eight successful First Amendment challenges against the Food and Drug Administration since 1999.  On January 22, 2014, Emord […]

Emord & Associates Cordially Invites You to A Critical Networking Event

Posted on by Peter Arhangelsky

All subscribers of the Emord blog, clients, and members of our LinkedIn Group  are cordially invited to attend our Gala Celebration on the occasion of Emord & Associates’ 20th Anniversary.  Over 160 people have already registered for this two day extravaganza featuring leading national figures in law, politics, journalism, nutrition science, and industry along with […]

Emord & Associates Expands Practice to Include California State Litigation and Regulatory Matters

Posted on by Peter Arhangelsky

Emord & Associates, P.C. is pleased to announce that effective December 2013 the firm expanded its state level practice to include direct representation of clients in the state courts of California and before California regulatory agencies.  The firm now directly represents clients in matters concerning California Proposition 65, California unfair competition claims (UCL), claims under […]

FDA’s Expansion of IND Regulations Impose Yet Another Major Regulatory Hurdle for Medical Food Companies

Posted on by Peter Arhangelsky

On September 10, 2013, FDA published a new guidance document restricting the scope of research permitted for dietary supplements and medical foods without first submitting an Investigational New Drug application (“IND”).  The document titled, “Guidance for Clinical Investigators, Sponsors, and IRBs:  Investigational New Drug Applications (INDs) – Determining Whether Human Research Studies Can Be Conducted […]

Does FDA’s Interpretation of “Nutrient Deficiency Diseases” in the Draft Medical Foods Guidance Create Room for Dietary Supplement Disease Claims?

Posted on by Peter Arhangelsky

The FDA’s revised Medical Food guidance turned heads last week when the agency declared that certain diseases related to nutrient deficiencies were off limits to medical foods.  We previously reported on that draft guidance document here.  By eliminating an entire class of diseases from the ambit of medical foods, the FDA left many existing products […]

FDA Proposes Rules Concerning Foreign Supplier Verification Programs (FSVP) Under the Food Safety Modernization Act (FSMA)

Posted on by Peter Arhangelsky

In July the FDA proposed two rules under the Food Safety Modernization Act (FSMA).  One rule concerns Foreign Supplier Verification Programs (FSVP).  The other concerns Accreditation of Third Party Auditors.  Under the FSVP rule, FDA plans to have importers verify that their suppliers meet the same U.S. safety standards required of domestic food producers.  The […]

Attorney Jonathan W. Emord Has Achieved The AV Preeminent Rating–The Highest Possible Rating From Martindale-Hubell

Posted on by Peter Arhangelsky

USNewswire–CLIFTON, VA (Aug. 8, 2013)–Martindale-Hubbell, a division of LexisNexis®, has confirmed that attorney Jonathan W. Emord still maintains the AV Preeminent Rating, Martindale-Hubbell’s highest possible rating for both ethical standards and legal ability, even after first achieving this rating in 1996. Please join us in congratulating Jonathan on this achievement.  

Commercialization of Qualified Health Claims

Posted on by Peter Arhangelsky

Qualified Health Claims permit nutrient-disease risk reduction claims to be made for dietary supplements without fear of FDA or FTC enforcement.  The FDA allows such claims in reliance on its “enforcement discretion,” following submission of a health claim petition.  The FDA’s “enforcement discretion” is a euphemism because the agency is constitutionally barred by precedent in […]

Emord & Associates Releases 2013 FDA Inspection Guide for Food and Dietary Supplement Companies

Posted on by Peter Arhangelsky

Emord & Associates has published an FDA Inspection Guide to help food and dietary supplement companies avoid common pitfalls associated with FDA inspections.  The guide, available for download online here, covers routine, cGMP, FSMA, and adulteration inspections.  It identifies the kinds of documents FDA ordinarily can and cannot obtain lawfully.  The guide provides general information […]

The Alliance for Natural Health USA and Certification Board for Nutrition Specialists Challenge CMS Proposed Rule Granting Hospital Ordering Privileges to Registered Dietitians

Posted on by Peter Arhangelsky

On April 5, 2013, the Alliance for Natural Health USA (ANH) and Certified Board for Nutrition Specialists (CBNS) each filed comments opposing a Medicare reform regulation proposed by the Centers for Medicare & Medicaid Services (CMS).  CMS proposed regulatory revisions to promote program efficiency, transparency, and burden reduction.  See 78 Fed. Reg. 9216-01 (Feb. 2013).  […]

Whether evaluating a concept, performing regulatory due diligence, maintaining or prosecuting regulatory filings, or contesting adverse litigation, Emord & Associates provides exceptional counsel for all your litigation and regulatory needs.

Virginia (Firm HQ)

11808 Wolf Run Lane
Clifton, VA 20124
Telephone: (202) 466-6937
Telecopier: (202) 466-6938